AzTrials
AzTrials

Acute Myelogenous LeukemiaPhase 1NCT03459859

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

A Phase 1 study testing Pevonedistat and Cytarabine in people with Acute Myelogenous Leukemia and AML, run by Justin Watts, MD at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult patients with… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pevonedistat and Cytarabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
21 May 2018to 25 Jun 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Confirmed diagnosis of one of the following:
  • Relapsed/refractory Acute Myelogenous Leukemia (AML) where no alternative life prolonging therapy exists. Treatment naïve patients may also be considered eligible if in the opinion of the investigator, these patients are unlikely to benefit from alternative therapy (eg conventional chemotherapy, hypomethylating agents).
  • Relapsed/refractory Myelodysplasic Syndrome (MDS) following at least two courses of a hypomethylating agent (eg azacitidine or decitabine). Patients intolerant of hypomethylating agents (irrespective of the number of cycles administered) will also be considered eligible. MDS eligibility limited to patients with intermediate, high or very high risk based on IPSS-R.
  • Adult male or female patients 18 years of age or older.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
  • Patients must satisfy the following laboratory criteria:
Show all 25Show fewer
  • Albumin > 2.7 g/dL
  • Total bilirubin ≤ upper limit of normal (ULN) except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin ≤1.5 x ULN of the direct bilirubin
  • Alanine transaminase (ALT) and Aspartate transaminase (AST) must be ≤ 2.5 × ULN
  • Creatinine 1.5 x ULN or calculated creatinine clearance > 50ml/min
  • Hemoglobin > 8 g/dL (prior red blood cell (RBC) transfusion allowed). Patients may be transfused to achieve this value. Elevated indirect bilirubin due to post-transfusion hemolysis is allowed.
  • White blood cell (WBC) count < 50,000/µL before administration of PEVONEDISTAT on Cycle 1 Day 1. Note: Hydroxyurea may be used to control the level of circulating leukemic blast cell counts to not lower than 10,000/µL during the study.
  • Suitable venous access to allow for all study related blood sampling (safety and research).
  • Estimated life expectancy, in the judgment of the Investigator, which will permit receipt of at least 6 weeks of treatment.
  • Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
  • Female patients who:
  • Are postmenopausal (see Appendix for definition) for at least 1 year before the screening visit, OR
  • Are surgically sterile, OR
  • If they are of childbearing potential:
  • Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
  • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).
  • Male patients, even if surgically sterilized (ie, status postvasectomy), who:
  • Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
  • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).
  • Able to undergo bone marrow aspiration at screening.

Who cannot join

  • Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug. Strong CYP3A inhibitors and CYP3A inducers are not permitted during the study.
  • Therapy with any investigational products, anti-neoplastic therapy, or radiotherapy within 14 days prior to Cycle 1 Day 1. Patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea during protocol treatment.
  • Candidates for standard and/or potentially curative treatments (a candidate is defined as a patient that is both eligible and willing to have these treatments)
  • Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period.
  • Grade 2 or higher diarrhea as defined by NCI CTCAE Version 4.03 despite optimal anti-diarrheal supportive care within 7 days prior to Cycle1 Day1.
  • Known cardiopulmonary disease defined as one of the following:
Show all 32Show fewer
  • Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg).
  • Cardiomyopathy or history of ischemic heart disease; patients with ischemic heart disease who have had acute coronary syndrome (ACS), MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll;
  • Clinically significant arrhythmia including:,history of polymorphic ventricular fibrillation or torsade de pointes); permanent atrial fibrillation [a fib], defined as a fib for ≥6 months; persistent a fib, defined as sustained afib >7 days and/or requiring cardioversion in the 4 weeks before screening; Grade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation. Patients with paroxysmal a fib are permitted to enroll. However, patients with < Grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll provided that their rate is controlled on a stable regimen.
  • Implantable cardioverter defibrillator;
  • Congestive heart failure (New York Heart Association (NYHA) Class III or IV; or Class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening), myocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug.
  • Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing);
  • Pulmonary hypertension.
  • Patients with Grade 2 or higher prolonged rate corrected QT (QTc) interval (≥ 481msec), calculated according to institutional guidelines.
  • Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography - LVEF assessment is not required for screening, and will only be done at the investigators discretion if clinically indicated..
  • Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis.
  • Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
  • Known human immunodeficiency virus (HIV) seropositive.
  • Known hepatitis B surface antigen seropositive (Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.)
  • Known or suspected active hepatitis C infections (Patients who are hepatitis C surface antigen-positive are eligible).
  • Females of child bearing potential who refuse to either practice 2 effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 30 days after the last dose of study drug.
  • Males of child bearing potential who refuse to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug. (Includes males surgically sterilized - i.e. status post vasectomy).
  • Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
  • Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
  • Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.
  • Symptomatic central nervous system (CNS) involvement.
  • Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Systemic anti-neoplastic therapy or radiotherapy within 14 days before the first dose of any study drug, except for hydroxyurea.
  • Patients with uncontrolled coagulopathy or bleeding disorder.
  • Life-threatening illness unrelated to cancer.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Miami

    Miami, Florida, 33136

Other trials in United States

About this study

Official title: An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)

The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS).

Being tested
Pevonedistat, Cytarabine
Medical subject headings
Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PevonedistatDrug

    Also called MLN4924

    Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

  • CytarabineDrug

    Also called ara-C

    Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.

Study groups in NCT03459859
Study groupRoleWhat they receive
Pevonedistat 10 LDAC 20ExperimentalDose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
Receives: Drug: Pevonedistat; Drug: Cytarabine
Pevonedistat 15 LDAC 20ExperimentalDose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
Receives: Drug: Pevonedistat; Drug: Cytarabine
Pevonedistat 20 LDAC 20ExperimentalDose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
Receives: Drug: Pevonedistat; Drug: Cytarabine
Pevonedistat 25 LDAC 20ExperimentalDose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
Receives: Drug: Pevonedistat; Drug: Cytarabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety Profile of Combination Pevonedistat/LDAC Therapy: Rate of Toxicity in Study Participants

    Rate of toxicity in study participants receiving at least one dose of combination Pevonedistat/LDAC protocol therapy, including determination of dose limiting toxicities (DLTs), serious adverse events (SAEs), and AEs. Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03.

    Measured: From Cycle 1 Day 1 to End of Study, up to 18 months

  2. Maximum Tolerated Dose (MTD) and Recommended Phase 2 (RP2D) Dose of Pevonedistat in Combination with Low Dose Cytarabine (LDAC)

    Determination of the MTD and RP2D of PEVONEDISTAT administered intravenously in patients with AML and advanced MDS when given in combination with low dose cytarabine (LDAC).

    Measured: From Cycle 1 Day 1 to End of Study, up to 18 months

Secondary outcomes (7)

  1. Rate of Efficacy in Study Participants

    Rate of complete response (CR) and partial response (PR) in study participants to Pevonedistat/LDAC combination therapy. Response will be determined using serial blood and bone marrow sampling throughout the course of treatment, and assessed according to revised/modified International Working Group (IWG) Response Criteria - Cheson et al. 2003 for AML and Cheson et al. 2006 for MDS.

    Morphologic complete remission (CR), cytogenetic CR, and molecular CR will be assessed based on blood counts, marrow blast percentage, cytogenetic studies and mutational analysis on every occasion the bone marrow is examined to assess for response.

    Measured: Up to 17 months

  2. Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Pevonedistat

    Pharmacokinetic effects of IV-administered PEVONEDISTAT in plasma will be measured when combined with LDAC. Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose. Pharmacokinetics (PK) parameters will be determined using serial blood sampling at specified time points to determine PK effects of PEVONEDISTAT in plasma when combined with LDAC. Non-compartmental methods of analysis will be used to determine PEVONEDISTAT PK parameters following IV dosing of patients in Cycle 1.

    Measured: Cycle 1 Days 1, 2 3, and 5

  3. Pharmacokinetics (PK): Time to Cmax (Tmax) of Pevonedistat

    Pharmacokinetic effects of IV-administered PEVONEDISTAT in plasma will be measured when combined with LDAC. Tmax is the time it takes a drug or other substance to reach the maximum concentration (Cmax). Pharmacokinetics (PK) parameters will be determined using serial blood sampling at specified time points to determine PK effects of PEVONEDISTAT in plasma when combined with LDAC. Non-compartmental methods of analysis will be used to determine PEVONEDISTAT PK parameters following IV dosing of patients in Cycle 1.

    Measured: Cycle 1 Days 1, 2, 3, and 5

  4. Pharmacokinetics (PK): Area Under the Plasma Concentration-Time curve from time 0 to 24 hours post-dose of Pevonedistat (AUC24hr).

    Pharmacokinetic effects of IV-administered PEVONEDISTAT in plasma will be measured when combined with LDAC. The area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24hr) will be assessed. Pharmacokinetics (PK) parameters will be determined using serial blood sampling at specified time points to determine PK effects of PEVONEDISTAT in plasma when combined with LDAC. Non-compartmental methods of analysis will be used to determine PEVONEDISTAT PK parameters following IV dosing of patients in Cycle 1.

    Measured: Cycle 1 Days 1, 2, 3, and 5

  5. Pharmacokinetics (PK): Terminal disposition phase half-life (t1/2) of Plasma Concentration of Pevonedistat

    Pharmacokinetic effects of IV-administered PEVONEDISTAT in plasma will be measured when combined with LDAC. Terminal phase half-life (t1/2) will be assessed. Half-life (t1/2) is the amount of time it takes for the drug concentration in the plasma to decline by half. Pharmacokinetics (PK) parameters will be determined using serial blood sampling at specified time points to determine PK effects of PEVONEDISTAT in plasma when combined with LDAC. Non-compartmental methods of analysis will be used to determine PEVONEDISTAT PK parameters following IV dosing of patients in Cycle 1.

    Measured: Cycle 1 Days 1, 2, 3, and 5

  6. Pharmacodynamics (PD): Induction Levels of CRL substrates

    Pharmacodynamics (PD) measurements will be obtained from serial blood and bone marrow sampling at specified time points to describe the PD effects of PEVONEDISTAT when combined with LDAC. The following endpoints will be analyzed: Induction of Cullin Ring Ligase (CRL) substrates by immunoblotting (e.g. nuclear factor (erythroid-derived 2)-like 2 (NRF2), chromatin licensing and DNA replication factor 1 (CDT1), pIKB and others).

    Measured: Baseline, Cycle 1 Days 1, 2, and 5; and End of Study, up to 18 months (+/- 10 days)

  7. Pharmacodynamics (PD): Induction Levels of Pathway Markers

    Pharmacodynamics (PD) measurements will be obtained from serial blood and bone marrow sampling at specified time points to describe the PD effects of PEVONEDISTAT when combined with LDAC. The following endpoints will be analyzed: Induction of pathway markers (eg SQ01 by polymerase chain reaction (PCR) in peripheral blood mononuclear cells) as well as other known indicators of pathway inhibition.

    Measured: Baseline, Cycle 1 Days 1, 2, and 5; and End of Study, up to 18 months (+/- 10 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2018
  2. Study start21 May 2018
  3. Primary completion25 Jun 2021
  4. Study completion25 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Dose escalation, traditional 3:3 design
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03459859
Sponsor's protocol ID
20180054
Other IDs
NCI-2019-06910
Status last verified
Dec 2021
First submitted
3 Mar 2018
Last updated
28 Dec 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Pevonedistat and Cytarabine in people with Acute Myelogenous Leukemia and AML, run by Justin Watts, MD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 25 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety Profile of Combination Pevonedistat/LDAC Therapy: Rate of Toxicity in Study Participants (time frame: From Cycle 1 Day 1 to End of Study, up to 18 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03459859.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2021; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in